Two studies imply that CCN1 has a favorable clinical effect in plasma cell neoplasms; Johnson et al. showed elevated serum CCN1 levels to be associated with a longer time to progression of monoclonal gammopathy of undetermined significance (MGUS) to overt MM and as such with a superior overall survival (Johnson et al. 2014), and Liu et al. showed increased CCN1 protein levels in the BM to be inversely associated with the severity of myeloma associated bone lesions (Liu et al. 2017). This evidence concerns the gene CCN1 and plasma cell myeloma.